janiecbros/E+ via Getty Images
- Fate Therapeutics (NASDAQ:FATE) disclosed on Friday that chief financial officer Edward Dulac will resign from the company, effective June 14.
- FATE added that it plans to appoint Scott Wolchko, president and CEO, as the CFO, principal financial and accounting officer, effective immediately after Dulac’s resignation.
- According to FATE, Wolchko previously served as the CFO of the company from the commencement of its operations until August 2020.
- SEC Filing
